BACKGROUND AND PURPOSE: To describe speech, neurological and imaging characteristics of a series of patients presenting with progressive spastic dysarthria as the first and predominant sign of a presumed neurodegenerative disease. METHODS: Participants were 25 patients with spastic dysarthria as the only or predominant speech disorder. Clinical features, pattern of MRI volume loss on voxel-based morphometry and pattern of hypometabolism on F18-fluorodeoxyglucose positron emission tomography (FDG-PET) scan are described. RESULTS: All patients demonstrated speech characteristics consistent with spastic dysarthria, including strained voice quality, slow speaking rate, monopitch and monoloudness, and slow and regular speech alternating motion rates. Eight patients did not have additional neurological findings on examination. Pseudobulbar affect, upper motor neuron pattern limb weakness, spasticity, Hoffman sign and positive Babinski reflexes were noted in some of the remaining patients. Twenty-three patients had electromyographic assessment and none had diffuse motor neuron disease or met El Escorial criteria for amyotrophic lateral sclerosis. Voxel-based morphometry revealed striking bilateral white matter volume loss affecting the motor cortex (BA 4), including the frontoparietal operculum (BA 43) with extension into the middle cerebral peduncle. FDG-PET showed subtle hypometabolism affecting the premotor and motor cortices in some patients, particularly in those who had a disease duration longer than 2 years. CONCLUSIONS: A neurodegenerative disorder that begins focally with spastic dysarthria due to involvement of the motor and premotor cortex and descending corticospinal and corticobulbar pathways is characterized. The descriptive label 'progressive spastic dysarthria' to best capture the dominant presenting feature of the syndrome is proposed.
BACKGROUND AND PURPOSE: To describe speech, neurological and imaging characteristics of a series of patients presenting with progressive spastic dysarthria as the first and predominant sign of a presumed neurodegenerative disease. METHODS:Participants were 25 patients with spastic dysarthria as the only or predominant speech disorder. Clinical features, pattern of MRI volume loss on voxel-based morphometry and pattern of hypometabolism on F18-fluorodeoxyglucose positron emission tomography (FDG-PET) scan are described. RESULTS: All patients demonstrated speech characteristics consistent with spastic dysarthria, including strained voice quality, slow speaking rate, monopitch and monoloudness, and slow and regular speech alternating motion rates. Eight patients did not have additional neurological findings on examination. Pseudobulbar affect, upper motor neuron pattern limb weakness, spasticity, Hoffman sign and positive Babinski reflexes were noted in some of the remaining patients. Twenty-three patients had electromyographic assessment and none had diffuse motor neuron disease or met El Escorial criteria for amyotrophic lateral sclerosis. Voxel-based morphometry revealed striking bilateral white matter volume loss affecting the motor cortex (BA 4), including the frontoparietal operculum (BA 43) with extension into the middle cerebral peduncle. FDG-PET showed subtle hypometabolism affecting the premotor and motor cortices in some patients, particularly in those who had a disease duration longer than 2 years. CONCLUSIONS:A neurodegenerative disorder that begins focally with spastic dysarthria due to involvement of the motor and premotor cortex and descending corticospinal and corticobulbar pathways is characterized. The descriptive label 'progressive spastic dysarthria' to best capture the dominant presenting feature of the syndrome is proposed.
Authors: Keith A Josephs; Joseph R Duffy; Tepanta R Fossett; Edythe A Strand; Daniel O Claassen; Jennifer L Whitwell; Patrick J Peller Journal: Arch Neurol Date: 2010-05
Authors: Martin R Turner; Jakub Scaber; John A Goodfellow; Melanie E Lord; Rachael Marsden; Kevin Talbot Journal: J Neurol Sci Date: 2010-05-10 Impact factor: 3.181
Authors: Jorge Jovicich; Silvester Czanner; Douglas Greve; Elizabeth Haley; Andre van der Kouwe; Randy Gollub; David Kennedy; Franz Schmitt; Gregory Brown; James Macfall; Bruce Fischl; Anders Dale Journal: Neuroimage Date: 2005-11-21 Impact factor: 6.556
Authors: Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen Journal: Brain Date: 2008-02-07 Impact factor: 13.501
Authors: Katerina A Tetzloff; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Sarah M Boland; Rene L Utianski; Hugo Botha; Matthew L Senjem; Christopher G Schwarz; Keith A Josephs; Jennifer L Whitwell Journal: Neurocase Date: 2018-05-25 Impact factor: 0.881
Authors: Keith A Josephs; Joseph R Duffy; Edythe A Strand; Mary M Machulda; Matthew L Senjem; Jeffrey L Gunter; Christopher G Schwarz; Robert I Reid; Anthony J Spychalla; Val J Lowe; Clifford R Jack; Jennifer L Whitwell Journal: Brain Date: 2014-08-11 Impact factor: 13.501
Authors: Joseph R Duffy; Edythe A Strand; Heather Clark; Mary Machulda; Jennifer L Whitwell; Keith A Josephs Journal: Am J Speech Lang Pathol Date: 2015-05 Impact factor: 2.408
Authors: Heather M Clark; Rene L Utianski; Farwa Ali; Hugo Botha; Jennifer L Whitwell; Keith A Josephs Journal: Am J Speech Lang Pathol Date: 2021-03-09 Impact factor: 2.408